Owlstone Medical
Mark Capone is a board member at Owlstone Medical. Mark has also served as the interim CEO of Nephrosant, Inc. from February 2021 to May 2022. Prior to that, they were a board observer at Crescendo Bioscience from April 2012 to April 2014. From January 2002 to February 2020, they were a board member at Myriad Genetics.
Mark Capone has a BS in Chemical Engineering from Penn State University and MS degrees in both Chemical Engineering (Biotechnology Emphasis) and Management from the Massachusetts Institute of Technology.
This person is not in the org chart
This person is not in any offices
Owlstone Medical
2 followers
A breathalyzer for disease. Breath Biopsy: The leader in non-invasive breath biomarker research. Our mission: Save 100,000 lives and $1.5B healthcare costs.